Lui S F, Wong K C, Li P K, Lai K N
Department of Medicine, Prince of Wales Hospital, Chinese University of Hong Kong, Shatin.
Am J Nephrol. 1992;12(1-2):55-60. doi: 10.1159/000168418.
Optimal route and frequency of administration of recombinant human erythropoietin (rHuEPO) have not yet been determined. There is some evidence to suggest that subcutaneous administration of rHuEPO may be more effective than the intravenous route in reversing renal anemia. It is also unclear whether rHuEPO is more effective when given by a large intermittent dose or by more frequent multiple divided doses. We have compared the effect of twice weekly versus once weekly subcutaneous administration of rHuEPO in two groups of haemodialysis patients. At the end of 12 weeks of treatment with rHuEPO, the mean haemoglobin levels had risen from 6.9 +/- (SD) 0.7 to 8.9 +/- 1.3 g/dl in the once weekly group and from 7.2 +/- 1.0 to 9.3 +/- 1.6 g/dl in the twice weekly group. The average doses of rHuEPO used during the study were 127 +/- 6 and 115 +/- 18 U/kg body weight/week for the once weekly and twice weekly groups, respectively. Subcutaneous administration of low-dose rHuEPO is effective in reversing renal anaemia. Similar responses were obtained with once weekly and twice weekly regimens.
重组人促红细胞生成素（rHuEPO）的最佳给药途径和频率尚未确定。有一些证据表明，皮下注射rHuEPO在纠正肾性贫血方面可能比静脉途径更有效。同样不清楚的是，大剂量间歇性给药还是更频繁的多次分剂量给药时rHuEPO更有效。我们比较了两组血液透析患者中，rHuEPO每周皮下注射一次与每周皮下注射两次的效果。在用rHuEPO治疗12周结束时，每周一次组的平均血红蛋白水平从6.9±（标准差）0.7升至8.9±1.3 g/dl，每周两次组从7.2±1.0升至9.3±1.6 g/dl。研究期间每周一次组和每周两次组使用的rHuEPO平均剂量分别为127±6和115±18 U/kg体重/周。皮下注射低剂量rHuEPO可有效纠正肾性贫血。每周一次和每周两次的给药方案产生了相似的反应。
